Literature DB >> 10962225

The hypothalamic-pituitary-thyroid axis in patients with schizophrenia.

A Baumgartner1, A Pietzcker, W Gaebel.   

Abstract

Serum concentrations of thyroxine (T(4)), triiodothyronine (T(3)), reverse triiodothyronine (rT(3)) and thyrotropine (TSH) were measured in 31 acutely ill in-patients with schizophrenia before and after four weeks of treatment with the phenothiazine derivative perazine. The serum levels of all the above hormones were also determined in 19 schizophrenic patients in remission who were receiving no medication, 20 schizophrenic patients in remission taking neuroleptic drugs, and 24 patients with residual-type schizophrenia. The serum levels of T(4) of acutely ill schizophrenic patients were elevated, while those of T(3), rT(3) and TSH were normal. Their T(4) levels showed a positive correlation with the severity of illness and the degree of clinical response to neuroleptic treatment. There was a significant fall in serum concentrations of T(4) and rT(3) during four weeks of drug treatment and the decrease was significantly correlated to clinical response. No abnormalities in the serum concentrations of any of the hormones measured were found in schizophrenic patients in remission or in residual-type schizophrenia. In conclusion, our results indicate that the elevated serum levels of T(4) may be specific for acutely ill schizophrenic patients and that neuroleptic medication may affect thyroid hormone metabolism, this interaction being involved in the mechanism of action of these drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10962225     DOI: 10.1016/s0920-9964(99)00187-5

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  8 in total

1.  Taurine and coenzyme Q10 synergistically prevent and reverse chlorpromazine-induced psycho-neuroendocrine changes and cataleptic behavior in rats.

Authors:  Mega O Oyovwi; Eze K Nwangwa; Benneth Ben-Azu; Tesi P Edesiri; Victor Emojevwe; John C Igweh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-11-04       Impact factor: 3.000

2.  Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics.

Authors:  Moses O Akiibinu; Omobola A Ogundahunsi; Ebenezer O Ogunyemi
Journal:  BMC Res Notes       Date:  2012-03-31

3.  Revisiting thyroid hormones in schizophrenia.

Authors:  Nadine Correia Santos; Patrício Costa; Dina Ruano; António Macedo; Maria João Soares; José Valente; Ana Telma Pereira; Maria Helena Azevedo; Joana Almeida Palha
Journal:  J Thyroid Res       Date:  2012-03-26

4.  Levothyroxine Augmentation in Clozapine Resistant Schizophrenia: A Case Report and Review.

Authors:  Ruohollah Seddigh; Somayeh Azarnik; Amir-Abbas Keshavarz-Akhlaghi
Journal:  Case Rep Psychiatry       Date:  2015-05-11

5.  Thyroid axis function after in-patient treatment of acute psychosis with antipsychotics: a naturalistic study.

Authors:  Robertas Bunevicius; Vesta Steibliene; Arthur J Prange
Journal:  BMC Psychiatry       Date:  2014-10-08       Impact factor: 3.630

6.  FT4 and TSH, relation to diagnoses in an unselected psychiatric acute-ward population, and change during acute psychiatric admission.

Authors:  Yuki Sakai; Valentina Iversen; Solveig Klæbo Reitan
Journal:  BMC Psychiatry       Date:  2018-07-28       Impact factor: 3.630

7.  Level of thyroid-stimulating hormone (TSH) in patients with acute schizophrenia, unipolar depression or bipolar disorder.

Authors:  Adam Wysokiński; Iwona Kłoszewska
Journal:  Neurochem Res       Date:  2014-04-11       Impact factor: 3.996

8.  Functional Status of Hypothalamic-Pituitary-Thyroid and Hypothalamic-Pituitary-Adrenal Axes in Hospitalized Schizophrenics in Shanghai.

Authors:  Yuncheng Zhu; Haifeng Ji; Lily Tao; Qing Cai; Fang Wang; Weidong Ji; Guohai Li; Yiru Fang
Journal:  Front Psychiatry       Date:  2020-02-27       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.